Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative

Simply Wall St.

Mar 18

Agenus (NasdaqCM:AGEN) has swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00, with net income of US$63.9 million for the period. The company has seen ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620401833"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620401833\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620401833?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-18 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620401833","market":"sg","top_or_hot":-1,"title":"Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative","media":"Simply Wall St.","content":"<div>\n<p>Agenus (NasdaqCM:AGEN) has swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00, with net income of US$63.9 million for the period. The company has seen ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agen/agenus/news/agenus-agen-q3-profit-of-us639-million-tests-longstanding-lo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 06:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agen/agenus/news/agenus-agen-q3-profit-of-us639-million-tests-longstanding-lo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agenus (NasdaqCM:AGEN) has swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00, with net income of US$63.9 million for the period. The company has seen ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agen/agenus/news/agenus-agen-q3-profit-of-us639-million-tests-longstanding-lo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉纳斯公司","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agen/agenus/news/agenus-agen-q3-profit-of-us639-million-tests-longstanding-lo","article_id":"2620401833","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agen/agenus/news/agenus-agen-q3-profit-of-us639-million-tests-longstanding-lo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620401833","pubTimestamp":1773786166,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Agenus (NasdaqCM:AGEN) has swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00, with net income of US$63.9 million for the period. The company has seen quarterly revenue move from US$23.5 million in Q2 2024 to US$26.8 million in Q4 2024 and then to US$30.2 million in Q3 2025, while EPS shifted from a loss of US$2.52 per share in Q2 2024 to a loss of US$2.00 in Q4 2024 and then to a profit of US$2.00 in Q3 2025, indicating a sharp turn in reported...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"Agenus(AGEN)第三季度利润6390万美元考验长期亏损叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":1.5},"content_text":"Agenus (NasdaqCM:AGEN) has swung to a profit in Q3 FY 2025, reporting total revenue of US$30.2 million and EPS of US$2.00, with net income of US$63.9 million for the period. The company has seen quarterly revenue move from US$23.5 million in Q2 2024 to US$26.8 million in Q4 2024 and then to US$30.2 million in Q3 2025, while EPS shifted from a loss of US$2.52 per share in Q2 2024 to a loss of US$2.00 in Q4 2024 and then to a profit of US$2.00 in Q3 2025, indicating a sharp turn in reported profitability. At a share price of US$3.99, these results put the focus on how durable the new margin profile might be. See our full analysis for Agenus. With the headline numbers on the table, the next step is to compare them with the prevailing stories about Agenus to see where the community narrative holds up and where the latest results start to shift expectations around growth and risk. See what the community is saying about Agenus NasdaqCM:AGEN Earnings & Revenue History as at Mar 2026 AdvertisementTTM loss of US$35 million despite Q3 profit  On a trailing twelve month basis, Agenus still reports a net loss of US$35.4 million and basic EPS of US$1.32 loss, even though Q3 FY 2025 on its own showed net income of US$63.9 million and EPS of US$2.00. Consensus narrative fans of the story point to forecast revenue growth of about 7.9% to 12.5% per year and earnings growth of about 24.5% per year. However, the fact that the last twelve months are still loss making means any case that Q3 marks a clean earnings turn is not fully backed by the data.\n     Supporters highlight that trailing revenue sits at US$106.8 million, alongside a low 1.3x P/S ratio compared with 5.9x for peers and 11.3x for the US Biotechs industry. At the same time, a five year record of losses growing around 9.7% per year and a TTM net loss of US$35.4 million keep the profitability debate open rather than resolved.    Low 1.3x P/S against DCF fair value of US$110.20  Agenus trades at a P/S of 1.3x based on trailing revenue of US$106.8 million and a share price of US$3.99, while the supplied DCF fair value is US$110.20, well above both the current price and the analysts' consensus target of US$12.33. Bulls argue that strong clinical programs and partnerships can justify that gap, and the current numbers give them some support but also some challenges.\n     The low P/S versus peers at 5.9x and the US Biotechs average at 11.3x lines up with the bullish view that the market may be underpricing potential future revenue and margin improvement. On the other hand, analysts still expect Agenus to be loss making over the next three years, and forecast that shares on issue could grow about 7% per year, which means any bullish argument has to work through both continued losses and dilution.    Bulls say the valuation gap here is too wide to ignore, while the latest earnings still leave plenty of questions, so if you want to see how they join the dots, take a look at the 🐂 Agenus Bull Case. Negative equity, dilution and higher share volatility  The latest risk snapshot highlights negative shareholders' equity, substantial dilution over the past year, and higher than market share price volatility over the last three months, even as trailing losses have narrowed from US$223.7 million to US$35.4 million over the data window provided. Bears focus on that capital structure and funding profile, and several of the reported figures strengthen their case.\n     They point out that a 31 year history of net losses, ongoing cash burn and the need for external funding can directly link to the recent dilution and negative equity position cited in the risk summary. They also highlight that analysts still do not forecast profitability within three years in their base, bullish or bearish scenarios, so the recent Q3 profit sits alongside balance sheet pressure and share volatility rather than replacing those concerns.    If you want to see how cautious investors frame those balance sheet and funding risks around these results, you can walk through their full case in the 🐻 Agenus Bear Case. Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Agenus on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With bulls and bears both finding support in the same set of numbers, it is worth stepping back and weighing the trade off for yourself rather than relying on any single narrative. If you want a clear view of the upside potential and the areas that could still go wrong, start by reviewing the 2 key rewards and 3 important warning signs. See What Else Is Out There Agenus still carries a trailing twelve month net loss, negative equity, ongoing dilution and higher share price volatility, so the path to stable profitability remains uncertain. If you want ideas with fewer balance sheet and funding concerns, compare these results with companies screened for stronger financial footing using the solid balance sheet and fundamentals stocks screener (42 results).  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}